Literature DB >> 17146589

Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.

S Papapetropoulos1, D C Mash.   

Abstract

Treatment-related motor fluctuations (MFs) and dyskinesias are considered one of the most important problems in the long-term management of Parkinson's disease (PD). However, only a few studies have focused on their characteristics during advanced and end stages of the disease. We therefore assessed MFs and dyskinesias in a cohort of 61 late/end stage patients with a clinical and pathological diagnosis of PD and investigated the influence of disease- and treatment-related variables on their occurrence. A total of 62.3% of our patients experienced "wearing-off" phenomena, 68.9% "on-off" motor fluctuations and 60.7% dyskinesias at advanced/end stage disease. Age at disease onset and disease duration were significantly associated with dyskinesias. A substantial number of patients experienced spontaneous resolution of their motor complications during the last two years of their disease without treatment modifications. The clinical heterogeneity of treatment-related motor complications in PD points towards a complex mechanism for their etiopathogenesis. Although advanced disease and L-dopa administration are closely tied to their development, other mechanisms involving synaptic aging, altered neuronal plasticity and post-synaptic degeneration may be involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146589     DOI: 10.1007/s00702-006-0603-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

Authors:  R D Sweet; F H McDowell
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

3.  Risk factors for levodopa-induced dyskinesias in Parkinson's disease.

Authors:  F Grandas; M L Galiano; C Tabernero
Journal:  J Neurol       Date:  1999-12       Impact factor: 4.849

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Disparities in the recording of Parkinson's disease on death certificates.

Authors:  Joyce C Pressley; Ming-Xin Tang; Karen Marder; Lucien J Cote; Richard Mayeux
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

7.  Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?

Authors:  S Papapetropoulos; A Lieberman; J Gonzalez; D C Mash
Journal:  Acta Neurol Scand       Date:  2005-06       Impact factor: 3.209

8.  Parkinsonism treated with levodopa: progression and mortality.

Authors:  M M Maier Hoehn
Journal:  J Neural Transm Suppl       Date:  1983

9.  Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.

Authors:  T Brannan; M D Yahr
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

10.  Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.

Authors:  S Papapetropoulos; A A Argyriou; J Ellul; E Chroni
Journal:  Eur J Neurol       Date:  2004-02       Impact factor: 6.089

View more
  7 in total

Review 1.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

2.  Late-stage Parkinson's disease: the Barcelona and Lisbon cohort.

Authors:  Miguel Coelho; Maria J Marti; Eduardo Tolosa; Joaquim J Ferreira; Francesc Valldeoriola; Mário Rosa; Cristina Sampaio
Journal:  J Neurol       Date:  2010-04-22       Impact factor: 4.849

3.  Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.

Authors:  Tommaso Martino; Donato Melchionda; Paolo Tonti; Vincenzo De Francesco; Alessandra Lalla; Luigi Maria Specchio; Carlo Avolio
Journal:  J Neural Transm (Vienna)       Date:  2016-09-10       Impact factor: 3.575

Review 4.  Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.

Authors:  Theresa A Zesiewicz; Kelly L Sullivan; Robert A Hauser
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

5.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

Review 6.  Treatment of advanced Parkinson's disease.

Authors:  Juan C Giugni; Michael S Okun
Journal:  Curr Opin Neurol       Date:  2014-08       Impact factor: 5.710

Review 7.  Inventory of real world data sources in Parkinson's disease.

Authors:  Audrey Tanguy; Linus Jönsson; Lianna Ishihara
Journal:  BMC Neurol       Date:  2017-12-08       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.